Trial Profile

BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pembrolizumab (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms BLAST AML-2; BLAST MRD AML-2

03 Feb 2025 Planned End Date changed from 1 Aug 2025 to 30 Jan 2026.
19 Aug 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
19 Aug 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com